AstraZeneca PLC (AZN.L) announced Ultomiris has been approved in the European Union for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria. The approval by the European Commission was based on interim results from the phase III clinical trial, the company said.
Ultomiris was previously approved in the EU for the treatment of adults with paroxysmal nocturnal haemoglobinuria and is also approved for the treatment of adults and children with atypical haemolytic uraemic syndrome.
Marc Dunoyer, CEO, Alexion, said: "Ultomiris has become the standard of care for the treatment of adults with PNH and we will make it available to this younger patient population as soon as possible."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.